D-Index & Metrics Best Publications

D-Index & Metrics D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines.

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Medicine D-index 113 Citations 61,146 742 World Ranking 2794 National Ranking 1604

Overview

What is he best known for?

The fields of study he is best known for:

  • Cancer
  • Gene
  • Internal medicine

His primary areas of study are Breast cancer, Internal medicine, Oncology, Cancer and Chemotherapy. His Breast cancer research integrates issues from Cancer research and Pathology. His Pathology research incorporates elements of DNA microarray, Hormone receptor and Gene expression profiling.

His Internal medicine study combines topics from a wide range of disciplines, such as Endocrinology and Gene expression. Lajos Pusztai combines subjects such as Survival rate, Regimen, Randomized controlled trial, Surgery and Triple-negative breast cancer with his study of Oncology. His Cancer study frequently links to adjacent areas such as Gene.

His most cited work include:

  • The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements (1880 citations)
  • Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer (1820 citations)
  • Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy (1509 citations)

What are the main themes of his work throughout his whole career to date?

His primary scientific interests are in Breast cancer, Internal medicine, Oncology, Cancer and Chemotherapy. His Breast cancer research is multidisciplinary, incorporating perspectives in Cancer research and Clinical trial, Bioinformatics, Pathology. His work deals with themes such as Gene expression, Gene and Immune system, which intersect with Cancer research.

His Bioinformatics research focuses on Gene expression profiling and how it connects with DNA microarray. In his study, Taxane is inextricably linked to Anthracycline, which falls within the broad field of Oncology. His biological study spans a wide range of topics, including Mutation, Regimen, Gynecology and Immunology.

He most often published in these fields:

  • Breast cancer (70.90%)
  • Internal medicine (60.83%)
  • Oncology (55.45%)

What were the highlights of his more recent work (between 2019-2021)?

  • Breast cancer (70.90%)
  • Internal medicine (60.83%)
  • Oncology (55.45%)

In recent papers he was focusing on the following fields of study:

Lajos Pusztai mostly deals with Breast cancer, Internal medicine, Oncology, Cancer and Triple-negative breast cancer. Lajos Pusztai does research in Breast cancer, focusing on Neoadjuvant therapy specifically. Lajos Pusztai focuses mostly in the field of Internal medicine, narrowing it down to matters related to Gastroenterology and, in some cases, Lymph and Immunohistochemistry.

His studies deal with areas such as Olaparib, Randomized controlled trial, Proportional hazards model and Hazard ratio as well as Oncology. His Cancer study integrates concerns from other disciplines, such as Mutation, Germline mutation, Gene, Somatic cell and Computational biology. His study looks at the relationship between Triple-negative breast cancer and fields such as PD-L1, as well as how they intersect with chemical problems.

Between 2019 and 2021, his most popular works were:

  • Pembrolizumab for Early Triple-Negative Breast Cancer. (228 citations)
  • Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial (90 citations)
  • Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. (19 citations)

In his most recent research, the most cited papers focused on:

  • Cancer
  • Gene
  • Internal medicine

His scientific interests lie mostly in Internal medicine, Breast cancer, Oncology, Triple-negative breast cancer and Neoadjuvant therapy. His work in Internal medicine covers topics such as Gastroenterology which are related to areas like Neutropenia, Cyclophosphamide, Phases of clinical research, Primary tumor and Biopsy. His research in Breast cancer is mostly focused on Trastuzumab.

His Oncology research incorporates themes from Cancer, Clinical trial, Olaparib, Randomized controlled trial and Tumor-infiltrating lymphocytes. His work carried out in the field of Triple-negative breast cancer brings together such families of science as Pembrolizumab, Cancer research, Lymph node, PD-L1 and Programmed cell death. His research in Neoadjuvant therapy intersects with topics in Estrogen Receptor Status, Circulating MicroRNA, KEGG, Proportional hazards model and Durvalumab.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer

Cornelia Liedtke;Chafika Mazouni;Kenneth R. Hess;Fabrice André.
Journal of Clinical Oncology (2008)

3088 Citations

Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy

Roman Rouzier;Charles M. Perou;W. Fraser Symmans;Nuhad Ibrahim.
Clinical Cancer Research (2005)

2386 Citations

The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements

Leming Shi;Laura H. Reid;Wendell D. Jones;Richard Shippy.
Nature Biotechnology (2006)

2353 Citations

Gene-expression signatures in breast cancer.

Christos Sotiriou;Lajos Pusztai.
The New England Journal of Medicine (2009)

1813 Citations

Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing

Garrett M Frampton;Alex Fichtenholtz;Geoff A Otto;Kai Wang.
Nature Biotechnology (2013)

1805 Citations

Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer

Aman U. Buzdar;Nuhad K. Ibrahim;Deborah Francis;Daniel J. Booser.
Journal of Clinical Oncology (2005)

1609 Citations

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.

José Baselga;José Baselga;Ian Bradbury;Holger Eidtmann;Serena Di Cosimo;Serena Di Cosimo.
The Lancet (2012)

1414 Citations

Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy

W. Fraser Symmans;Florentia Peintinger;Christos Hatzis;Radhika Rajan.
Journal of Clinical Oncology (2007)

1317 Citations

The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti–HER-2 Therapy and Personalized Medicine

Jeffrey S. Ross;Elzbieta A. Slodkowska;W. Fraser Symmans;Lajos Pusztai.
Oncologist (2009)

1288 Citations

Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study

Rita R Nanda;Laura Q M Lq Chow;Claire Dees;Raanan R Berger.
Journal of Clinical Oncology (2016)

1168 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Lajos Pusztai

Siraj M. Ali

Siraj M. Ali

Foundation Medicine

Publications: 179

Vincent A. Miller

Vincent A. Miller

EQRx

Publications: 172

Jorge S. Reis-Filho

Jorge S. Reis-Filho

Memorial Sloan Kettering Cancer Center

Publications: 155

Gabriel N. Hortobagyi

Gabriel N. Hortobagyi

The University of Texas MD Anderson Cancer Center

Publications: 149

Christos Sotiriou

Christos Sotiriou

Université Libre de Bruxelles

Publications: 139

Charles M. Perou

Charles M. Perou

University of North Carolina at Chapel Hill

Publications: 138

Giuseppe Viale

Giuseppe Viale

University of Milan

Publications: 136

Jeffrey S. Ross

Jeffrey S. Ross

Foundation Medicine

Publications: 132

Gordon B. Mills

Gordon B. Mills

Oregon Health & Science University

Publications: 131

Martine Piccart

Martine Piccart

Université Libre de Bruxelles

Publications: 126

Fabrice Andre

Fabrice Andre

Institut Gustave Roussy

Publications: 124

Sherene Loi

Sherene Loi

Peter MacCallum Cancer Centre

Publications: 124

Funda Meric-Bernstam

Funda Meric-Bernstam

The University of Texas MD Anderson Cancer Center

Publications: 115

Carsten Denkert

Carsten Denkert

Philipp University of Marburg

Publications: 106

Eric P. Winer

Eric P. Winer

Harvard University

Publications: 104

Giuseppe Curigliano

Giuseppe Curigliano

University of Milan

Publications: 99

Trending Scientists

J. Jeffrey Inman

J. Jeffrey Inman

University of Pittsburgh

Ben J. Sugden

Ben J. Sugden

Microsoft (United States)

Gary A. Molander

Gary A. Molander

University of Pennsylvania

Inmaculada Rodríguez-Ramos

Inmaculada Rodríguez-Ramos

Spanish National Research Council

Alfred Nordheim

Alfred Nordheim

University of Tübingen

David Cortez

David Cortez

Vanderbilt University

Yoshikazu Kurosawa

Yoshikazu Kurosawa

Fujita Health University

L. Scott Johnson

L. Scott Johnson

Towson University

Giulio Levi

Giulio Levi

Istituto Superiore di Sanità

Jörg Overmann

Jörg Overmann

Leibniz Association

Caryl E. Sortwell

Caryl E. Sortwell

Michigan State University

Detlef Zillikens

Detlef Zillikens

University of Lübeck

Benedict R. Lucchesi

Benedict R. Lucchesi

University of Michigan–Ann Arbor

Steven R. Houser

Steven R. Houser

Temple University

Marjan van den Akker

Marjan van den Akker

Goethe University Frankfurt

Gunnar Myrdal

Gunnar Myrdal

Stockholm University

Something went wrong. Please try again later.